Jul 13, 2026 12:02AM
Jun 30, 2026 02:44AM
May 25, 2026 03:33AM
May 15, 2026 02:55AM
May 8, 2026 02:48AM
May 8, 2026 02:48AM
May 8, 2026 02:47AM Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
Mar 23, 2026 03:50AM
Feb 6, 2026 06:17AM
Aug 25, 2025 03:26AM
May 15, 2025 04:56AM
Apr 1, 2025 06:14AM
Mar 25, 2025 03:08AM
Mar 3, 2025 03:17AM Therapeutic Goods Administration decides not to register lecanemab in Australia
Feb 28, 2025 08:11AM
Feb 18, 2025 02:13AM
Jan 31, 2025 07:12AM
Jan 26, 2025 09:50PM
Jan 13, 2025 09:49PM
Oct 31, 2024 07:43PM
Jun 9, 2024 10:55PM FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
Jun 10, 2023 07:34AM
Jun 7, 2023 11:02PM
May 21, 2023 11:01PM
May 16, 2023 11:19PM
May 15, 2023 11:01PM
Apr 3, 2023 10:48PM
Apr 3, 2023 02:19AM BioArctic: New lecanemab-data presented at the AD/PD™ 2023 conference
Mar 31, 2023 02:14AM
Mar 19, 2023 10:43PM
Mar 13, 2023 11:01PM
Mar 5, 2023 09:50PM
Dec 22, 2022 09:44PM
Nov 29, 2022 10:34PM
Nov 29, 2022 10:15PM BioArctic's partner Eisai presents results of lecanemab Phase 3 confirmatory Clarity AD study for Early Alzheimer's disease at CTAD conference
Nov 21, 2022 03:40AM
Sep 27, 2022 11:10PM
Aug 5, 2022 02:14AM
Jul 26, 2022 02:16AM
Jul 5, 2022 11:04PM
May 9, 2022 10:42PM
Sep 27, 2021 11:01PM Eisai initiates rolling submission for the US FDA Biologics license application of lecanemab for early Alzheimer's disease under the accelerated approval pathway

15,546 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All